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Summary: Total HIV-1 DNA was quantified in HIV-1/HCV coinfected patients receiving 
pIFN-α treatment. Total HIV-1 DNA remained stable before, during, and after pIFN-α 
treatment, which questions the benefit of pIFN-α as an immunotherapeutic agent for reducing 
the HIV-1 reservoir. 
ABSTRACT  
 
Pegylated interferon-alpha (pIFN-α) is suggested to lower HIV-1 DNA load in antiretroviral 
therapy (ART) treated patients. We studied the kinetics of total HIV-1 DNA levels in 40 HIV-
1/hepatitis C (HCV) coinfected patients, treated with pIFN-α for HCV and categorized into 
three groups according to start of ART: Chronic HIV-1 infection (n=22), acute HIV-1 infection 
(n=8), no-ART (n=10). Total HIV-1 DNA levels were quantified in 247 PBMC samples and 
remained stable before, during, and after pIFN-α treatment in all three groups. Our study-
results question the benefit of pIFN-α as an immunotherapeutic agent for reducing the HIV-1 
reservoir. 
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Eradication of human immunodeficiency virus type 1 (HIV-1) infection is not attainable by 
antiretroviral drugs alone, due to the HIV-1 reservoir formed early during acute infection [1]. 
Pegylated interferon alpha (pIFN-α), used to treat hepatitis C virus (HCV) infection, 
represents an interesting candidate to reduce the HIV-1 reservoir due to its variable antiviral 
and immune stimulating properties against HIV-1 [2, 3]. However, effects of pIFN-α on total 
HIV-1 DNA levels, a well-validated marker of the HIV-1 reservoir [4], in antiretroviral therapy 
(ART) receiving, HIV-1 infected patients is not fully understood and there are conflicting 
results concerning the effects and mechanisms of pIFN-α.  
To examine benefits of pIFN-α treatment in reducing total HIV-1 DNA levels, we 
conducted a study including 40 HIV-1/HCV coinfected patients from the Swiss HIV Cohort 
Study (SHCS), and the Zurich Primary HIV Infection Study (ZPHI). Unique to our study, we 
included patients from three groups: (i) HIV-1 chronic, (ii) HIV-1 acute - both stratified 
according to time to initiation of ART after HIV-1 infection – and (iii) a no-ART HIV-1 infected 
group, all with long follow-up times post pIFN-α treatment. We hypothesized that pIFN-α 
would lead to sustained reduction of the total HIV-1 DNA.   
 
PATIENTS, MATERIALS, AND METHODS 
 
Study Design 
This is a retrospective study using prospectively collected clinical information and blood 
samples obtained within protocols of the ZPHI and SHCS (supplementary information 1) and 
stored in respective biobanks. Complete inclusion and exclusion criteria can be found in the 
supplementary information 2. In brief, inclusion criteria for HIV-1 infected, ART treated 
patients were: (i) HCV-coinfection and a history of pIFN-α/RBV treatment for ≥24 weeks; (ii) 
no history of virological failure; (iii) no history of ART interruption; (iv) on suppressive 
BACKGROUND 
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combination ART; (v) documented ART-adherence of ≥95% [5]. Exclusion criteria were: ≥1 
blip during ART before start of pIFN-a/RBV. Inclusion criteria for no-ART HIV-1 infected 
patients were: (i) HCV-coinfection and history of pIFN-α/RBV treatment for ≥24 weeks and, 
(ii) ART-naïve at time of pIFN-α/RBV initiation, during and ≥1 year after pIFN-a/RBV 
treatment.  
Patient groups were defined as chronic when ART was started ≥6 months after the 
estimated date of infection (EDI), as acute when ART was started <6 months after EDI, and 
as no-ART when patients were not on ART as defined above. Information on pIFN-α dosage 
and administration can be found in the supplemental information 3. 
 
Quantitation of total HIV-1 DNA 
Genomic DNA was isolated from ≥2 million cryopreserved PBMCs using DNeasy Blood & 
Tissue Kits (Qiagen) according to the manufacturer’s description except that two elution 
steps, each with 45 µl of pre-heated (70°C) AE elution buffer, were applied. Total HIV-1 DNA 
was quantified in duplicates by qPCR with cycling profile: 95 °C 5 min, 50x (95 °C 15 sec, 
60 °C 30 sec) using forward and reverse primers H7  and H1, alongside the probe mf381tq. 
To measure genomic in ut, the single copy reference gene CC Chemokine Receptor 5 
(CCR5), was quantified using primers mf51 and mf52 with the probe mf73tq (Supplementary 
Table 1). Quantification was done using an in-house HIV-1 all-in-one Standard (supplemental 
information 4, supplementary figure 1 A and B).  
 
Quantitation of HIV-1 viral load 
Values for HIV-1 RNA copies/mL plasma were obtained from patients’ clinical history. These 
values were measured using Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay versions 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy131/4924783
by E-Library Insel user
on 19 March 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
1 and 2. Detection limits were either 40 or 20 HIV-1 RNA copies/mL plasma for version 1 and 
2, respectively.    
 
Cell Counts 
CD4+, CD8+, and CD3+ T-cells were quantified by flow cytometry following routine 
laboratory protocols.  
 
Statistical analysis 
Wilcoxon matched-pairs signed rank test were applied to assess changes in total HIV-1 
DNA, HIV-1 viral load, and cell counts using GraphPad Prism Version 5.04 (La Jolla, CA).  
 
 
RESULTS 
 
Patient population and HCV treatment   
Forty HIV-1/HCV-coinfected individuals were categorized into three patient groups according 
to their stage of HIV-1 infection at the time of ART initiation: (i) chronic HIV-1 infection 
(n=22), (ii) acute HIV-1 infection (n=8), and (iii) no-ART (n=10). Baseline demographics and 
clinical characteristics are depicted in Table 1.  
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We quantified total HIV-1 DNA in 247 PBMC samples with a mean number of time points 
(range) per patient of 6.6 (2-12) in the chronic, 5.6 (2-10) in the acute and 5.7 (3-9) in the no-
ART groups. The average follow-up time after pIFN-α treatment is depicted in Table 1.  
We analysed total HIV-1 DNA levels in PBMCs obtained prior to pIFN-α treatment 
(Figure 1). Values were grouped according to time of pIFN-α treatment and median values 
were calculated. We found that total HIV-1 DNA levels (median HIV-1 DNA copies/106 
genomic equivalents [range]) were 0.15 log10 higher in the chronic (1652 [67.4-9807]) 
versus the acute group (1156 [50.2-2516.7], p=0.07), as well as 0.74 log10 higher than in the 
no-ART group (298.1 [6.9-3635], p=0.06).  
We evaluated the effect of pIFN-α/RBV treatment on total HIV-1 DNA. We observed 
no decrease in total HIV-1 DNA levels during administration of pIFN-α/RBV in any of the 
three patient groups (Figure 1). Some patients across all groups (chronic n=8, acute n=4, no-
ART n=1) had even moderate increases in total HIV-1 DNA levels during pIFN-α treatment (p 
>0.05). After pIFN-α treatment, total HIV-1 DNA returned to the same levels as before pIFN-α 
treatment in the acute and chronic groups. In the no-ART group, total HIV-1 DNA levels after 
pIFN-α treatment were higher (p=0.02) than total HIV-1 DNA levels before pIFN-α treatment 
(individual total HIV-1 DNA profiles provided in supplementary figures 2A, 2B, 2C). As 
interferon is known to cause general lymphopenia, we calculated the total HIV-1 DNA levels 
normalised to CD4+ T-cell counts, but observed no change in the total HIV-1 DNA kinetics. 
Of note, four patients (C6, C19, C20, and A4) underwent repeated pIFN-α treatments due to 
non-response to previous HCV treatment. In all four patients, no sustained decrease in total 
HIV-1 DNA levels was detected (supplementary figures 2A and 2B). 
  
 
Total HIV-1 DNA levels remain stable during pIFN-α treatment 
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As IFN-α is known to have anti-viral effects against HIV-1, we studied effects of pIFN-α HIV-1 
on viral load in the no-ART group. The mean viral load decreased by 0.8 log10 (p=0.004) 
during treatment as compared to pre-treatment levels. After pIFN-α treatment cessation, viral 
load returned to pre-treatment levels (Figure 1D). All patients in the chronic and acute groups 
maintained undetectable viral loads (<20-40 HIV-1 RNA copies/mL plasma) during pIFN-α 
treatment (supplementary figure 3).  
 
pIFN-α -induced lymphopenia observed in T-cell subsets 
As expected, during pIFN-α treatment we observed a significant drop in mean values (cell 
count/µl of blood) of CD4+ (p=<0.0001), CD8+ (p=<0.0001), and CD3+ (p=<0.0001) T-cells 
and in absolute lymphocyte counts in comparison to pre-pIFN-α levels. After treatment stop, 
all lymphocyte subsets returned to pre-treatment levels (supplementary figure 4).  
 
DISCUSSION 
In 40 well-characterized HIV-1/HCV-coinfected patients, we longitudinally assessed 
effects of pIFN-α treatment on total HIV-1 DNA levels in PBMCs, a surrogate marker for the 
HIV-1 reservoir [4]. We observed that total HIV-1 DNA levels remained stable during and 
after pIFN-α in comparison to pre-treatment levels, also in patients who underwent repeated 
pIFN-α treatments. 
To dissect potential effects of pIFN-α with regard to the timing of ART initiation, we 
analysed three different HIV-1/HCV coinfected patient groups: (i) HIV-1 infected patients 
treated with ART during chronic HIV-1 infection; (ii) HIV-1 infected patients treated with ART 
during acute HIV-1 infection, and (iii) untreated HIV-1 infected patients. Baseline total HIV-1 
DNA levels in the acute group were 0.15 log10 lower compared to patients treated during the 
pIFN-α decreases the HIV-1 viral load in the no-ART group 
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chronic stage of infection. This observation is in line with several studies, showing that 
patients treated in the early stage of HIV-1-infection have substantially lower total HIV-1 DNA 
levels compared to individuals treated during chronic phase [6]. The low total HIV-1 DNA 
levels observed in the no-ART group are most likely due to selection of patients controlling 
HIV-1 well in absence of ART, which is associated with low total HIV-DNA levels [7]. Six of 
the ten patients in this group showed viral loads of <5,000 HIV-1 RNA copies/mL plasma 
before pIFN-α treatment, with one being an elite controller (Figure 1D) [7]. Viral load was 
assessed in the no-ART group before, during, and after pIFN-α treatment and a reduction of 
0.8 log10 observed. This finding is in line with the results of several clinical trials reporting an 
approximately 0.5-1 log10 decrease in viral load when pIFN-α is administered to HIV-1–
infected persons in absence of ART [8]. 
With regard to effects of pIFN-α administration on the total HIV-1 DNA levels, our 
findings differ from previous studies. Sun et al. (2014) reported a moderate reduction of 
CD4+ T-cell-associated total and integrated HIV-1 DNA in 12 HIV-1/HCV-coinfected 
individuals treated with pIFN-α for a median of 51 weeks [9]. In their study, reductions of HIV-
1 DNA occurred mainly in patients without treatment-associated lymphopenia, suggesting 
that the decline in HIV-1 DNA levels did not result simply from lymphocellular toxicity of pIFN-
α treatment. In our study, all patients exhibited pIFN-α associated lymphopenia and no 
reduction in HIV-1 DNA levels from PBMC was observed. A recent study [10] found results 
more in line with ours as authors did not detect any change in total HIV-1 DNA levels in 10 
patients receiving a short-term pIFN-α treatment of 28 days.  
A possible explanation for the absence of a HIV-1 DNA decrease is that our assay 
measures total HIV-1 DNA, however, this is not only a measure of replication competent 
viruses [11]. The study from Morón-López et al. [10] where the replication competent 
reservoir was measured by viral outgrowth assay (VOA) in patients receiving pIFN-α/RBV 
showed no change in the number of infectious units per million CD4+ T-cells (IUPM) from 
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patients on ART. The absence of an HIV-1 DNA decrease is unlikely resulting from 
insufficient pIFN-α treatment as (i) all our patients exhibited lymphopenia, (ii) the no-ART 
group showed an RNA decline of 0.8 log10, and (iii) 90% had a sustained virological 
response of the HCV infection.  
The strength of this work is that, to our knowledge, our study is to date the largest one 
investigating the effects of pIFN-α on total HIV-1 DNA levels in people on suppressive 
antiretroviral therapy. The longitudinal nature is unprecedented with patients being followed 
up for as long as 112 months post pIFN-α. Limitations are that due to the retrospective 
nature of our study, we investigated only effects of pIFN-α on total HIV-1 DNA in 
cryopreserved patient PBMCs. As we did not investigate cells from other biological 
compartments, we may have missed tissue-specific pIFN-α effects. We also did not 
differentiate between integrated and non-integrated proviral HIV-1 DNA. However, it has 
been shown that after one year of ART almost no linear unintegrated HIV-1 DNA exists 
anymore [12] and our ART-treated patients were virologically suppressed for ≥1 year before 
of pIFN-α administration. Moreover, we did not use the VOA, which is suggested as the gold 
standard for HIV-1 latency, although it fails to detect a considerable fraction of inducible 
latently infected cells [13]. Finally, our study population did not include patients who received 
pIFN-α administration close to the time of HIV-1 acquisition. Thus, a potential beneficial 
pIFN-α  effect on the establishment of the HIV-1 reservoir, which is formed early after HIV-1 
infection [14] cannot be ruled out. The only study exploring pIFN-α together with antiretroviral 
treatment in 12 acutely HIV-1 infected patients, however, found a total HIV-1 DNA decay that 
was similar to that found in acutely infected ART treated patients alone [12, 15]. Thus, pIFN-
α would probably need to be administered much earlier, which is hardly achievable in clinical 
practice.  
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 In summary, our longitudinal study in different well-characterized patient groups did 
not reveal any substantial effect of pIFN-α on the HIV-1 reservoir as measured by a total 
HIV-1 DNA qPCR assay in PBMCs. Thus, our study does not support a sustainable effect of 
pIFN-α as an immunotherapeutic intervention in patients who have initiated ART during acute 
or chronic HIV-1 infection or who are off ART to reduce the HIV-1 reservoir. 
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Table 1. SHCS Patient Characteristics at baseline (pre IFN-α/Ribavirin treatment). Significant p values are 
italicised.   
Data chronic group 
(n=22) 
acute group 
(n=8) 
no-ART group  
(n=10) 
chronic 
versus acute 
(p=) 
Age (years) at time of 
pIFN-α treatment, mean 
(range) 
45 (37-55) 38 (27-45) 42 (32-53) 0.005 
Gender (%)     
Male  21 (95.5) 8 (100) 7 (70) >0.9 
Female  1 (4.5) 0 (0) 3 (30) >0.9 
Ethnicity (%)     
Caucasian 22 (100) 8 (100) 10 (100) n.a. 
Risk Groupa (%)     
MSM 5 (22.7) 7 (87.5) 4 (40) 0.003 
HET 1 (4.5) 1 (12.5) 1 (10) 0.46 
IDU 11 (50) 0 2 (20) 0.01 
IDU or HET 3 (13.6) 0 3 (30) 0.54 
IDU or MSM 2 (9.1) 0 0 >0.9 
HIV Subtype (%)     
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B 22 (100) 7 (87.5) 8 0.27 
Non B 0 1 (12.5) 1 0.27 
Unknown 0 0 1  
Time under Suppressive 
ARTb, months (range) 
42.4 (7-110) 39.4 (4-98) n.a.d 0.9 
HCV Genotype     
1  9 3 1 >0.9 
2  0 0 1 >0.9 
3  9 1 6 0.21 
4  2 2 0 0.28 
Unknown 2 2 2 n.a. 
HCV Treatmentc     
pIFN-α 1 0 0 >0.9 
pIFN-α + RBV 21 7 10 0.47 
IFN-α + RBV 0 1 0 0.27 
Treatment Duration 
(weeks), mean (range) 
48.1 (24-68) 40.5 (24-48) 38.7 (20-51) 0.04 
SVR 12 or 24e with IFN-α 
(%) 
    
Yes 19 (86.4) 7 (87.5) 9 (90) >0.9 
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No 1 (4.5) 1 (12.5) 1 (10) 0.46 
Unknown 2 (9.1) 0 0 >0.9 
Follow up (months)f, 
mean (range) 
46.6 (3-112) 13.3 (0-34) 43.9 (3-99) 0.003 
a
MSM= men who have sex with men, HET= heterosexual, IDU= intravenous drug use. 
b
Suppressive ART defined as treatment controlling HIV-1 RNA <50 copies/mL plasma 
c
pIFN-α-=Pegylated Interferon alpha, RBV= Ribavirin, IFN-α= Interferon alpha 
d
n.a. = Not applicable as were not on antiretroviral treatment at the time of Interferon administration 
e
Sustained Virological Response against HCV 
f
After stop of Interferon-alpha treatment 
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Figure 1: Total HIV-1 DNA levels remain stable before, during, and after pIFN-α 
treatment periods in all three groups (chronic, acute, and no-ART) of HIV-1/HCV 
coinfected patients with the HIV-1 viral load decreasing in the no-ART group.  
Total HIV-1 DNA values are calculated to 106 genomic equivalents (CCR5). Treatment period 
is displayed on the x axis, and median total HIV-1 DNA load on the y axis. Statistical 
significance is displayed as *(p ≤0.05), or ns (no significance). Each symbol and 
corresponding number (for example C1, A1, and N1) refers to an individual patient in the 
chronic, acute, or no-ART group. (A) Patients who started antiretroviral therapy (ART) during 
the chronic stage of HIV-1 infection and later went on to receive pIFN-α for a HCV infection. 
(B) Patients who started ART during the acute stage of HIV-1 infection and later received 
pIFN-α for a HCV infection. (C) Patients who received no ART at the time of pIFN-α 
administration. (D) Pegylated interferon alpha decreases the HIV-1 viral load in the no-ART 
group. HIV-1 viral load (RNA copies/mL plasma) is plotted as mean values for before, during, 
and after pIFN-α treatment periods. The samples below the limit of detection (L.O.D.) appear 
below the dashed line. The L.O.D. is below 40 and 20 HIV-1 RNA copies/mL plasma for 
Roche Cobas Taqman HIV-1 assay version 1 and 2, respectively. Statistical significance is 
displayed as ** (p ≤0.01), or ns (no significance). Individual patients are depicted by a symbol 
and corresponding ID. 
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Figure 1. 
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